Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients

ObjectiveThis study aimed to evaluate the efficacy of Olverembatinib in patients with relapsed and persistent minimal residual disease-positive Philadelphia chromosome-positive acute lymphoblastic leukemia.MethodsWe conducted a retrospective analysis of clinical characteristics in 22 patients diagno...

Descripción completa

Detalles Bibliográficos

Autores principales:	Xinwen Jiang, Minran Zhou, Junjie Ma, Qingli Ji, Xiaoqing Li, Sai Ma, Chunyan Chen
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2025-10-01
Colección:	Frontiers in Medicine
Materias:	acute lymphoblastic leukemia Philadelphia chromosome-positive relapsed MRD-positive tyrosine kinase inhibitor
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1662512/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!